Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Category: #health  By Pankaj Singh  Date: 2019-10-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from Phase ½ results were presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

MRTX849 has exhibited clinical activity in patients with solid tumors with KRAS G12C mutations, colorectal cancer and non-small cell lung cancer. As the trial continues to enroll patients, maximum tolerated dose is expected to be established soon.

Charles M. Baum, President and CEO, Mirati Therapeutics has been reported to say that patients who suffer from KRAS G12C mutation in their tumors often endure poor prognosis as their ailment is resistant to standard care and targeted therapeutics have not yet been developed for them.

He added that Phase 1/2 trial of MRTX849 has demonstrated the safety data and efficacy required for an effective KRAS therapy. MRTX849 is being tested in a number of patients suffering from KRAS G12C mutated cancers with the hope of soon being able to provide them with much needed therapy.

Of the 17 patients enrolled in the first-in-human ongoing Phase ½ of MRTX849, 10 patients are suffering from non-small cell lung cancer, 4 patients are affected with colorectal cancer and 3 have other tumor types. Trial objectives include pharmacodynamics, tolerability, pharmacokinetics and safety of the therapy.

Pasi A. Jänne, MRTX849-001 investigator and Director of The Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute said that finding a therapeutic approach for KRAS mutations would have tremendous clinical impact for cancer patients as these mutations are the most common oncogenic alteration.

Cancer Discovery, which is a journal of the American Association of Cancer Researchers and publishes major advances in research and clinical trials also published an article about MRTX849. The article on the preclinical studies of MRTX849 describes the challenging research path that was undertaken to develop a therapy that directly targets KRAS.

 

Source Credit: https://ir.mirati.com/news-releases/news-details/2019/Mirati-Therapeutics-Presents-First-Clinical-Data-Of-Phase-12-Trial-Of-MRTX849-At-The-2019-AACR-NCI-EORTC-International-Conference-On-Molecular-Targets-And-Cancer-Therapeutics/default.aspx



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Appili gets FDA approval to expand the clinical trial of favipiravir
Appili gets FDA approval to expand the clinical trial of favipiravir
By Pankaj Singh

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application ...

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
By Pankaj Singh

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The tria...

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...